NASDAQ: NNNNAnbio Biotechnology Stock
$6.61+0.04 (+0.61%)
Updated Apr 17, 2025
NNNN Price
$6.61
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$5.18
52 Week High
$7.82
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
-0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NNNN Overview
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NNNN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NNNN
Ranked#90 of 463
Ranked#90 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important NNNN news, forecast changes, insider trades & much more!
NNNN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NNNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NNNN's short-term assets ($18.77M) exceed its short-term liabilities ($527.75k)
Short-term Liabilities Financials
NNNN's short-term assets ($18.77M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
NNNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
There are 30 more NNNN due diligence checks available for Premium users.
Valuation
NNNN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$18.9M
Liabilities
$527.8k
Debt to equity
0.03
NNNN's short-term assets ($18.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NNNN's short-term assets ($18.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NNNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Anbio Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.